Juliana M Kling1, Virginia M Miller2, Nirubol Tosakulwong3, Timothy Lesnick3, Kejal Kantarci4. 1. Division of Women's Health Internal Medicine, Mayo Clinic, Scottsdale, AZ, 13737 North 92nd Street, Scottsdale, AZ 85260. 2. Departments of Surgery and Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN. 3. Department of Health Sciences Research, Mayo Clinic, Rochester, MN. 4. Department of Radiology, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: Little is known about how menopausal hormone treatment (HT) may influence the development of white matter hyperintensities (WMHs) in the brain. This study evaluated the associations of changes in levels of pituitary-ovarian hormones during HT and changes in WMH. METHODS: Women (n = 78 adherent to treatment) enrolled in the Kronos Early Estrogen Prevention Study underwent brain magnetic resonance imaging, and blood collection before and after 48 months of randomization to 0.45 mg/d oral conjugated equine estrogen (oCEE) daily, 50 μg/d transdermal 17β estradiol (tE2), or placebo pills and patches. Women in the active treatment groups also received oral 200 mg/d micronized progesterone the first 12 days of the month. Estradiol (E2), estrone (E1), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were measured in serum by high sensitivity liquid chromatography/mass spectrometry at baseline and following 48 months of HT. Longitudinal change in WMH volume was determined from fluid-attenuated inversion recovery magnetic resonance imaging using a semiautomated image segmentation algorithm. RESULTS: Serum levels of FSH, LH, E1, or E2 did not associate with WMH volume at baseline. After 48 months of treatment, smaller increases in WMH associated with decreases in FSH from baseline in the tE2 group and increases in E1 in both tE2 and oCEE groups. Changes in LH did not associate with changes in WMH in any group. CONCLUSIONS: Circulating levels of pituitary-ovarian hormones associate with changes in WMH volume in recently menopausal women using HT. Whether these relationships would be influenced by different doses of tE2 or oCEE remains to be determined. : Video Summary:http://links.lww.com/MENO/A590.
OBJECTIVE: Little is known about how menopausal hormone treatment (HT) may influence the development of white matter hyperintensities (WMHs) in the brain. This study evaluated the associations of changes in levels of pituitary-ovarian hormones during HT and changes in WMH. METHODS: Women (n = 78 adherent to treatment) enrolled in the Kronos Early Estrogen Prevention Study underwent brain magnetic resonance imaging, and blood collection before and after 48 months of randomization to 0.45 mg/d oral conjugated equine estrogen (oCEE) daily, 50 μg/d transdermal 17β estradiol (tE2), or placebo pills and patches. Women in the active treatment groups also received oral 200 mg/d micronized progesterone the first 12 days of the month. Estradiol (E2), estrone (E1), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were measured in serum by high sensitivity liquid chromatography/mass spectrometry at baseline and following 48 months of HT. Longitudinal change in WMH volume was determined from fluid-attenuated inversion recovery magnetic resonance imaging using a semiautomated image segmentation algorithm. RESULTS: Serum levels of FSH, LH, E1, or E2 did not associate with WMH volume at baseline. After 48 months of treatment, smaller increases in WMH associated with decreases in FSH from baseline in the tE2 group and increases in E1 in both tE2 and oCEE groups. Changes in LH did not associate with changes in WMH in any group. CONCLUSIONS: Circulating levels of pituitary-ovarian hormones associate with changes in WMH volume in recently menopausal women using HT. Whether these relationships would be influenced by different doses of tE2 or oCEE remains to be determined. : Video Summary:http://links.lww.com/MENO/A590.
Authors: Giuseppe Verdile; Bu B Yeap; Roger M Clarnette; Satvinder Dhaliwal; Melanie S Burkhardt; S A Paul Chubb; Karl De Ruyck; Mark Rodrigues; Pankaj D Mehta; Jonathan K Foster; David G Bruce; Ralph N Martins Journal: J Alzheimers Dis Date: 2008-06 Impact factor: 4.472
Authors: Carey E Gleason; N Maritza Dowling; Whitney Wharton; JoAnn E Manson; Virginia M Miller; Craig S Atwood; Eliot A Brinton; Marcelle I Cedars; Rogerio A Lobo; George R Merriam; Genevieve Neal-Perry; Nanette F Santoro; Hugh S Taylor; Dennis M Black; Matthew J Budoff; Howard N Hodis; Frederick Naftolin; S Mitchell Harman; Sanjay Asthana Journal: PLoS Med Date: 2015-06-02 Impact factor: 11.069
Authors: Kejal Kantarci; Val J Lowe; Timothy G Lesnick; Nirubol Tosakulwong; Kent R Bailey; Julie A Fields; Lynne T Shuster; Samantha M Zuk; Matthew L Senjem; Michelle M Mielke; Carey Gleason; Clifford R Jack; Walter A Rocca; Virginia M Miller Journal: J Alzheimers Dis Date: 2016-05-07 Impact factor: 4.472
Authors: Kejal Kantarci; Nirubol Tosakulwong; Timothy G Lesnick; Samantha M Zuk; Val J Lowe; Julie A Fields; Jeffrey L Gunter; Matthew L Senjem; Megan L Settell; Carey E Gleason; Lynne T Shuster; Kent R Bailey; N Maritza Dowling; Sanjay Asthana; Clifford R Jack; Walter A Rocca; Virginia M Miller Journal: Neurology Date: 2018-03-21 Impact factor: 9.910
Authors: Steven Jett; Eva Schelbaum; Grace Jang; Camila Boneu Yepez; Jonathan P Dyke; Silky Pahlajani; Roberta Diaz Brinton; Lisa Mosconi Journal: Front Aging Neurosci Date: 2022-07-19 Impact factor: 5.702